Registered Malawi · PMRA

ASHIENRO 10% 10%W/V INJECTION

ENROFLOXACIN

PMPB/PL418/22 INJECTION INN generic

What it does

Enrofloxacin is an antibiotic used to treat bacterial infections in animals.

Commonly used for: bacterial infections, infections in pets

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
PMPB/PL418/22
Registration date
17/04/2015
Expiry date
30/06/2016
Status
Registered
Active ingredient
ENROFLOXACIN
Dosage form
INJECTION
Strength
-
Pack size
-
Therapeutic class
-
RxNorm RxCUI
24192
Manufacturer / MAH
-
Applicant / LTR
-
Country of origin
-

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:42 · updated 2026-09-19 04:30:23

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.

About this medicine

Enrofloxacin is an antibiotic used to treat bacterial infections in animals.

What it treats

  • bacterial infections
  • infections in pets

How it works

It kills bacteria or stops their growth, helping to treat infections.

Who it's for

It is mainly used for pets and animals suffering from infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: enrofloxacin

BNF-referenced

Enrofloxacin is a fluoroquinolone antibiotic that is used primarily in veterinary medicine but has applications in human medicine. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are critical for bacterial DNA replication, transcription, and repair. This leads to bacterial cell death, making it effective against a broad spectrum of gram-negative and some gram-positive bacteria.

Indications

  • Bacterial infections
  • Respiratory tract infections
  • Urinary tract infections
  • Skin infections
  • Gastrointestinal infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients.

Adults: Refer to the specific product guidelines for dosing information, as it can vary based on the indication and formulation used.

Mechanism of action

Enrofloxacin exerts its antibacterial effect through the inhibition of bacterial DNA gyrase and topoisomerase IV, which are essential enzymes for DNA replication and transcription. By interfering with these enzymes, enrofloxacin disrupts the normal function of the bacterial cell, leading to cell death.

Pharmacodynamics

Enrofloxacin has a bactericidal effect, meaning it kills bacteria rather than merely inhibiting their growth. Its activity is concentration-dependent, meaning that higher concentrations lead to more significant antibacterial effects. The drug has a broad spectrum of activity against many gram-negative bacteria, including Pseudomonas aeruginosa, as well as some gram-positive organisms.

Pharmacokinetics

Enrofloxacin is well-absorbed after oral administration, with peak plasma concentrations typically achieved within 1 to 2 hours. It is widely distributed throughout the body, including into tissues and fluids, and has good penetration into the central nervous system. The elimination half-life varies but is generally between 4 to 8 hours in humans. Enrofloxacin is primarily metabolized in the liver, and its metabolites, including ciprofloxacin, are also active against bacteria.

Contra-indications

  • Hypersensitivity to enrofloxacin or any of its components
  • Use in growing animals due to potential effects on cartilage development

Adverse effects

  • Gastrointestinal disturbances such as vomiting and diarrhea
  • Central nervous system effects including seizures and ataxia
  • Tendon rupture or damage, particularly in larger breed dogs
  • Possible cartilage damage in young animals

Interactions

  • Antacids or products containing aluminum, magnesium, or iron may reduce the absorption of enrofloxacin
  • Cationic agents may interfere with its antimicrobial activity
  • Concurrent use with other nephrotoxic drugs may increase the risk of renal toxicity

Precautions

  • Use with caution in animals with a history of seizures or renal impairment
  • Monitor for signs of adverse reactions during therapy
  • Not for use in animals with known hypersensitivity to fluoroquinolones

Pregnancy

Safety during pregnancy has not been established, use only if benefits outweigh risks.

Breast-feeding

Safety during lactation has not been fully established, use with caution.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

  • Injectable solution
  • Oral tablets
  • Oral suspension

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: enrofloxacin

PubChem CID 71188

Molecular formula: C19H22FN3O3

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.